

# Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients

NCT07059026

---

**Status** RECRUITING  
**Sponsor** ITAC (Instituto de Trasplantes y Alta Complejidad)  
**Enrollment** 200 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Adult patients (≥ 18 years) undergoing allogeneic HSCT in specialized centers that, as part of their usual follow-up protocol, carry out basic screening (laboratory/clinical) for TMA and in which patients consent (within the general transplant consent), to have their data used in observational studies.
- Patients with ≥ 3/laboratory/clinical diagnostic markers of TMA in two consecutive assessments within 14 days, namely: 1-Elevated Schistocytes in peripheral blood; 2-LDH above the upper normal limit; 3-De novo thrombocytopenia or requirement for platelet transfusion; 4-De novo anemia or requirement for red blood cell transfusion; 5-High blood pressure (≥140/90); 6-Protein/creatinine ratio > 1mg/mg or proteinuria ≥ 30mg/dl in a random sample).
- Patients with suspected/diagnosed TMA who have signed the specific consent for the study.

### Exclusion (1)

- Participation in an interventional treatment study of any therapy for TMA.

## Locations (1 total)

---

Instituto de Trasplantes de Alta Complejidad (ITAC), Buenos Aires, Argentina